Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma

Assessment of CD8+ cell infiltration and PD-L1 expression on intratumoral immune cells identified a subgroup of HPV+ OPSCC patients with excellent clinical outcomes. Immunophenotyping tumors provided prognostic information beyond that provided by existing TNM-based staging systems. Human papilloma virus–positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC) represents a distinct subgroup of head and neck cancers associated with clinical outcomes that are not accurately categorized by existing tumor–node–metastasis-based staging methods. Given the significant impact of immune parameters, such as tumor-infiltrating lymphocytes (TIL) in many cancers, we sought to determine if immunophenotyping tumors can improve categorization of HPV+ OPSCCs for prognostic purposes. In a cohort of 190 patients with HPV+ OPSCC, we quantified and determined the localization of CD8+ TILs, as well as PD-L1–expressing tumor cells (TC) and immune cells (IC). The prognostic significance of these parameters on overall survival (OS) was evaluated, and their contribution to existing prognostic models was determined. High CD8+ TIL abundance (≥30% on stromal or intratumoral ICs) was seen in 61.3% patients and was associated with improved OS [HR, 0.4; 95% confidence interval (CI), 0.2–0.9; P = 0.017]. Although the expression of PD-L1 on TC was not prognostic, high expression of PD-L1 on ≥5% of intratumoral ICs was found in 38.5% patients and was significantly associated with improved OS (HR, 0.37; 95% CI, 0.15–0.93; P = 0. 023). Both high intratumoral IC PD-L1 expression and abundant CD8+ TILs in HPV+ OPSCCs identify subgroups of patients with excellent outcomes and provide additional prognostic information beyond existing staging systems. Cancer Immunol Res; 6(3); 295–304. ©2018 AACR.

[1]  V. Budach,et al.  The PD‐1/PD‐L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK‐ROG) , 2017, International journal of cancer.

[2]  J. Taube,et al.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[3]  K. Harrington,et al.  Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141 , 2017 .

[4]  K. Pitman,et al.  Evaluation of proposed staging systems for human papillomavirus‐related oropharyngeal squamous cell carcinoma , 2017, Cancer.

[5]  R. Decker,et al.  A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma , 2017, JAMA oncology.

[6]  B. Panizza,et al.  Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy. , 2017, Oral oncology.

[7]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Su Jin Heo,et al.  PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients , 2016, Scientific Reports.

[9]  A. Hakimi,et al.  The head and neck cancer immune landscape and its immunotherapeutic implications. , 2016, JCI insight.

[10]  A. Chaturvedi,et al.  Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. , 2016, Oral oncology.

[11]  E. King,et al.  Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors , 2016, Oncotarget.

[12]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[13]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[14]  Shao Hui Huang,et al.  Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. , 2016, The Lancet. Oncology.

[15]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[16]  D. van Baarle,et al.  Differences in T-cell infiltrates and survival between HPV+ and HPV- oropharyngeal squamous cell carcinoma , 2016, Future science OA.

[17]  P. Stern,et al.  Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma , 2015, British Journal of Cancer.

[18]  John Cho,et al.  Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Kevin P. White,et al.  Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes , 2014, Clinical Cancer Research.

[20]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[21]  E. King,et al.  Staging and treatment of oropharyngeal cancer in the human papillomavirus era , 2014, Head & neck.

[22]  J. Galon,et al.  Imaging , Diagnosis , Prognosis Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer , 2014 .

[23]  Jacques Ferlay,et al.  Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[25]  E. King,et al.  Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer , 2013, British Journal of Cancer.

[26]  T. Nyberg,et al.  CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. , 2013, European journal of cancer.

[27]  N. Kokot,et al.  Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. , 2013, Head & neck oncology.

[28]  J. Lewis p16 Immunohistochemistry As a Standalone Test for Risk Stratification in Oropharyngeal Squamous Cell Carcinoma , 2012, Head and Neck Pathology.

[29]  H. Johansson,et al.  Tumor Infiltrating CD8+ and Foxp3+ Lymphocytes Correlate to Clinical Outcome and Human Papillomavirus (HPV) Status in Tonsillar Cancer , 2012, PloS one.

[30]  R. Shaw,et al.  Evaluation of Human Papilloma Virus Diagnostic Testing in Oropharyngeal Squamous Cell Carcinoma: Sensitivity, Specificity, and Prognostic Discrimination , 2011, Clinical Cancer Research.

[31]  Zlatko Trajanoski,et al.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Fisher,et al.  Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[34]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[35]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[36]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[37]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[38]  A. Garden,et al.  An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center , 2013, Cancer.

[39]  Patrice Ravel,et al.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. , 2013, Cancer research.